FDA, Big Pharma collaborate on genetic tests

Seven of the world's biggest drug makers are banding together to create a research consortium that will develop genetic tests that can identify patients vulnerable to dangerous adverse events. Under prodding from the FDA, Pfizer, Roche and others will back a research program that will develop tests for serious liver toxicity as well as Stevens-Johnson syndrome. Their work will go into the public domain, available to anyone wishing to develop a genetic test on that data. The development of pharmacogenetics is considered crucial to a new generation of biotech drugs, which are intended to produce higher efficacy rates among smaller groups of patients.

- check out this release for details on the program
- read the article from The New York Times

Related Articles:
House overhauls, passes PDUFA. Report
Bickering may stall trial database. Report
PDUFA debate highlights drug safety issues. Report
Senate toughens drug safety supervision in PDUFA bill. Report

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.